Turn Therapeutics Inc.
Turn Therapeutics (Nasdaq: TTRX) develops topical therapies for inflammatory skin disease and fungal nail infections, with its lead candidate GX-03 being studied for moderate-to-severe eczema and advanced for onychomycosis. The non-systemic, non-biologic formulation contains polyhexanide and is intended to modulate… From the company’s description.
In fiscal 2025, Turn Therapeutics Inc. reported a net loss of $3.19M. Operations used $2.56M in cash.
Dotted labels explain each measure.
What Turn Therapeutics Inc. does
In the company’s own words
Turn Therapeutics (Nasdaq: TTRX) develops topical therapies for inflammatory skin disease and fungal nail infections, with its lead candidate GX-03 being studied for moderate-to-severe eczema and advanced for onychomycosis. The non-systemic, non-biologic formulation contains polyhexanide and is intended to modulate inflammation while providing antimicrobial activity. Turn also has FDA-cleared medical-device formulations for wound management and dermatitis, which it licenses or supplies through commercial partners, and conducts exploratory research on a thermostable intranasal vaccine-delivery platform. Its business centers on dermatology drug development and partner-led commercialization of medical devices; it does not describe reportable operating segments. In October 2025, Turn entered a multi-year agreement with Medline to develop, manufacture, and commercialize products using its PermaFusion platform, with Medline leading distribution through professional and retail networks in more than 100 countries and territories. Turn’s portfolio includes the GX-03 formula and the PermaFusion® delivery platform. Its website is www.turntherapeutics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WESTLAKE VILLAGE, CA
- Fiscal year end
- December
- CIK
- 2023016
- SIC
- 2834
Financial performance, year by year
Fiscal 2025–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Turn Therapeutics Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Turn Therapeutics Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Turn Therapeutics Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Turn Therapeutics Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Turn Therapeutics Inc.'s last four quarterly filings that the numbers alone won't show?”